Filing Details

CUSIP No. 753431105

Schedule 13D

Page 2 of 5

---

1.	Names of Reporting Persons   Sean Berrier
2.	Check the Appropriate Box if a Member of a Group   (a) [  ]  (b) [  ]
3.	Sec Use Only
4.	Source of Funds     OO
5.	Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e)   [  ]
6.	Citizenship or Place of Organization    United States
			7.	Sole Voting Power   -0- shares
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
			8.	Shared Voting Power   50,333,333 shares*
			9.	Sole Dispositive Power   -0- shares
			10.	Shared Dispositive Power   50,333,333 shares*
11.		Aggregate Amount Beneficially Owned by Each Reporting Person   50,333,333 shares*
12.		Check if the Aggregate Amount in Row (11) Excludes Certain Shares     [  ]
13.		Percent of Class Represented by Amount in Row (11)       27.6%#
14.		Type of Reporting Person (See Instructions)   IN

 

* 54,600,000 as of December 2, 2020.

# 30.5% as of December 2, 2020.

CUSIP No. 753431105

Schedule 13D

Page 3 of 5

---

Item 1. Security and Issuer

 

This Statement relates to the common stock, $0.001 par value per share (the Common Stock), of Rapid Therapeutic Science Laboratories, Inc., a Nevada corporation (the Issuer or the Company). The principal executive offices of the Issuer are located at 5580 Peterson Lane, Suite 200, Dallas, Texas 75240.

 

Item 2. Identity and Background

 

(a)This Statement is being filed by Sean Berrier (the Reporting Person). 

 

(b)Mr. Berriers business address is 5580 Peterson Lane, Suite 200, Dallas, Texas 75240. 

 

(c)Mr. Berriers principal business occupation is Senior Vice President (a non-executive officer position) of the Issuer. 

 

(d)The Reporting Person has not, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). 

 

(e)The Reporting Person has not, during the last five years, been party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. 

 

(f)Mr. Berrier is a citizen of the United States. 

 

Item 3. Source and Amount of Funds or Other Consideration

 

Effective on December 2, 2020, Texas MDI, Inc., which is controlled by Mr. Donal R. Schmidt, Jr., the Chief Executive Officer and Director of the Issuer, which owned 140,000,000 shares of the Issuers Common Stock, representing 78.1% of the Issuers then outstanding shares of Common Stock, distributed such shares of Common Stock pro-rata and in-kind to its shareholders, for no consideration (the Distribution). Pursuant to the Distribution, Mr. Berrier, who was a shareholder of TMDI, received 54,600,000 shares of Common Stock, in-kind and for no consideration.

 

Effective on or around December 2020, Mr. Berrier sold (a) 11,666,667 shares of common stock for $500,000 ($0.30 per share); (b) 2,000,000 shares of common stock for $500,000 ($0.25 per share); and (c) 600,000 shares of common stock for $150,000 ($0.25 per share), respectively, in private transactions.

 

Item 4. Purpose of Transaction

 

The information set forth in Item 3 is hereby incorporated by reference into this Item 4.

 

The Reporting Person acquired the securities for investment purposes. In the future, depending on general market and economic conditions affecting the Issuer and other relevant factors, the Reporting Person may purchase additional securities of the Issuer or dispose of some or all of the securities he currently owns from time to time in open market transactions, private transactions or otherwise.

 

The Reporting Person does not currently have any plans or proposals which relate to or would result in the following described:

 

(a)The acquisition by any person of additional securities of the Issuer, or the disposition of securities of the Issuer; 

 

(b)An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries; 

CUSIP No. 753431105

Schedule 13D

Page 4 of 5

---

(c)A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries; 

 

(d)Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board; 

 

(e)Any material change in the present capitalization or dividend policy of the Issuer; 

 

(f)Any other material change in the Issuers business or corporate structure, including but not limited to, if the Issuer is a registered closed-end investment company, any plans or proposals to make any changes in its investment policy for which a vote is required by section 13 of the Investment Company Act of 1940; 

 

(g)Changes in the Issuers charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person; 

 

(h)Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association; 

 

(i)A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to section 12(g)(4) of the Act; or 

 

(j)Any action similar to any of those enumerated above. 

 

Item 5. Interest in Securities of the Issuer

 

(a)As of the close of business on February 3, 2021, the Reporting Person beneficially owns in aggregate 50,333,333 shares of Common Stock representing 27.6% of the 182,261,608 shares of the Companys issued and outstanding Common Stock on such date (as confirmed by the Issuers transfer agent). 

 

(b)Mr. Berrier has sole power to vote or to direct the vote and to dispose or to direct the disposition of the 50,333,333 shares of Common Stock held by Mr. Berrier. 

 

(c)See Item 3, above. 

 

(d)No other person has the right to receive or the power to direct the receipt of dividends from or the proceeds from the sale of the securities beneficially owned by the Reporting Person. 

 

(e)N/A. 

 

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

 

None.

 

Item 7. Material to Be Filed as Exhibits

 

None.

 

 

 

 

CUSIP No. 753431105

Schedule 13D

Page 5 of 5

---

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

 

Dated: February 3, 2021	/s/ Sean Berrier
	Sean Berrier